NCT06046482 2025-10-22Phase II Trial of Magrolimab and Cetuximab With Pembrolizumab or Docetaxel for Recurrent/Metastatic Head Neck Squamous Cell CarcinomaM.D. Anderson Cancer CenterPhase 2 Terminated4 enrolled 11 charts